Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.

In Oncology
by ClinOwl

Combination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and […]